Move Over Botox - Beverly Hills' Simoni Plastic Surgery to Hold the First Ever Dys...( BEVERLY HILLS Calif. Oct. 13 /- a hre...),Health

BEVERLY HILLS, Calif., Oct. 13 /PRNewswire/ -- Botox® parties are so last year. With the recent FDA approval of Dysport, Botox® finally has its first and only rival. Consumers and the plastic surgery industry at large are expecting some changes to the anti-aging game as a result of this new competition. Many are hoping this rivalry between Botox® and Dysport will result in not only price reduction, but quality improvement, both of which will benefit consumers directly.

For years, Allergan's Botox® has dominated the market without any major competition. The unmatched and cost effective results provided by Botox® have made it the number one cosmetic procedure in America. No other aesthetic product is as popular nor has hosted as many parties throughout the country.

Botulinum toxin A is the active ingredient of both Dysport and Botox. The diluted Botulinum toxin A relaxes the muscles that cause wrinkles, decreasing unsightly lines. Allergan, the company behind Botox®, has enjoyed an unrivaled market for years, repeatedly raising its prices every year. Even the recent downturn in the economy has not seemed to diminish the need for this luxury item. "Interestingly the number of Botox® requests has increased in recent months," explains Dr. Payman Simoni, a Beverly Hills plastic surgeon. "As more people cannot afford costly surgical procedures, a temporary yet affordable fix has become more attractive," he said.

"With Dysport, medical manufacturer Ipsen introduces the only other FDA approved botulinum toxin, and the happy days of no competition may be over for Allergan," said Dr. Simoni. "This may spur on pricing competition that will benefit consumers. Also this competition may trigger further attempts to improve on to the next 'bigger and better' products," he conc
'/>"/>